Inventor · disambiguated record
Adrian R. Krainer
Also filed as: KRAINER ADRIAN · KRAINER ADRIAN R
14 granted patents·23 pending applications·218 citations·filing 2001–2024
93Inventor score
Files withCOLD SPRING HARBOR LABORATORY8BIOGEN MA INC7IONIS PHARMACEUTICALS INC5ISIS PHARMACEUTICALS INC5COLD SPRING HARBOR LAB2
Top patents by PatentIndex Score
37 records- 0197US9717750B2Compositions and methods for modulation of SMN2 splicing in a subjectBIOGEN MA INC·Filed 2015·Granted Aug 1, 2017·26 cites·42 claims
- 0297US8980853B2Compositions and methods for modulation of SMN2 splicing in a subjectBENNETT C FRANK·Filed 2010·Granted Mar 17, 2015·48 cites·4 claims
- 0397US8361977B2Compositions and methods for modulation of SMN2 splicingISIS PHARMACEUTICALS INC·Filed 2006·Granted Jan 29, 2013·62 cites·48 claims
- 0494US11096956B2Antisense oligomers and uses thereofSTOKE THERAPEUTICS INC·Filed 2018·Granted Aug 24, 2021·11 cites·20 claims
- 0594US9976143B2Targeted augmentation of nuclear gene outputCOLD SPRING HARBOR LABORATORY·Filed 2015·Granted May 22, 2018·25 cites·42 claims
- 0694US8946183B2Compositions and methods for modulation of SMN2 splicingISIS PHARMACEUTICALS INC·Filed 2012·Granted Feb 3, 2015·12 cites·14 claims
- 0791US11083745B2Antisense oligomers for treatment of autosomal dominant mental retardation-5 and Dravet SyndromeCOLD SPRING HARBOR LABORATORY·Filed 2016·Granted Aug 10, 2021·6 cites·36 claims
- 0890US10696969B2Targeted augmentation of nuclear gene outputCOLD SPRING HARBOR LABORATORY·Filed 2018·Granted Jun 30, 2020·4 cites·21 claims
- 0987US9518259B2Compounds and methods for modulating interaction between proteins and target nucleic acidsRIGO FRANK·Filed 2011·Granted Dec 13, 2016·19 cites·14 claims
- 1087US2024238326A1Compositions and methods for modulation of smn2 splicing in a subjectBIOGEN MA INC·Filed 2023·Application pending·0 cites
- 1186US10344282B2Compositions and methods for modulation of IKBKAP splicingIONIS PHARMACEUTICALS INC·Filed 2018·Granted Jul 9, 2019·2 cites·20 claims
- 1284US2025270563A1Targeted augmentation of nuclear gene outputCOLD SPRING HARBOR LABORATORY·Filed 2024·Application pending·0 cites
- 1379US11352624B2Reducing nonsense-mediated MRNA decayCOLD SPRING HARBOR LABORATORY·Filed 2020·Granted Jun 7, 2022·1 cites·11 claims
- 1477US10647983B2Reducing nonsense-mediated mRNA decayCOLD SPRING HARBOR LABORATORY·Filed 2014·Granted May 12, 2020·2 cites·15 claims
- 1576US2020181613A1Compositions and methods for modulation of smn2 splicingBIOGEN MA INC·Filed 2019·Application pending·0 cites
- 1675US2020376018A1Compositions and methods for modulation of smn2 splicing in a subjectBIOGEN MA INC·Filed 2019·Application pending·0 cites
- 1772US11066668B2Compositions and methods for modulation of IKBKAP splicingIONIS PHARMACEUTICALS INC·Filed 2019·Granted Jul 20, 2021·0 cites·10 claims
- 1870US2022372473A1Antisense compounds and uses thereofIONIS PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1970US2015353929A1Compositions and methods for modulation of smn2 splicingISIS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 2068US2018291376A1Compositions and methods for modulation of smn2 splicingBIOGEN MA INC·Filed 2017·Application pending·0 cites
- 2168US2021108208A1Targeted augmentation of nuclear gene outputCOLD SPRING HARBOR LABORATORY·Filed 2020·Application pending·0 cites
- 2267US11236330B2Antisense compounds and uses thereofIONIS PHARMACEUTICALS INC·Filed 2018·Granted Feb 1, 2022·0 cites·20 claims
- 2366US2022088058A1Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndromeCOLD SPRING HARBOR LABORATORY·Filed 2021·Application pending·0 cites
- 2465US2022118000A1Antisense oligomers and uses thereofSTOKE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2565US2017088835A1Compositions and methods for modulation of smn2 splicingBIOGEN MA INC·Filed 2016·Application pending·0 cites
- 2665US2024360450A1Antisense oligonucleotide therapy for h3.3 k27m diffuse midline gliomasCOLD SPRING HARBOR HARBOR LABORATORY·Filed 2022·Application pending·0 cites
- 2762US2019030058A1Compositions and methods for modulation of smn2 splicing in a subjectBIOGEN MA INC·Filed 2018·Application pending·0 cites
- 2858US2015025231A1Compositions and methods for modulation of ikbkap splicingISIS PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 2958US2019211330A1Compositions and methods for treatment of spinal muscular atrophyIONIS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 3056US2023302036A1Compositions for treatment of spinal muscular atrophyCONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECN·Filed 2021·Application pending·0 cites
- 3154US2015275211A1Antisense compounds and uses thereofISIS PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 3253US2014357558A1Compositions and methods for treatment of spinal muscular atrophyHUA YIMIN·Filed 2012·Application pending·0 cites
- 3351US2014011977A1Chimeric molecules to modulate gene expressionCOLD SPRING HARBOR LAB·Filed 2013·Application pending·0 cites
- 3446US2005054836A1Chimeric molecules to modulate gene expressionCOLD SPRING HARBOR LAB·Filed 2001·Application pending·0 cites
- 3541US2011159587A1Chimeric Molecules to Modulate Gene ExpressionKRAINER ADRIAN R·Filed 2010·Application pending·0 cites
- 3636US2012149757A1Compositions and methods for modulation of smn2 splicingKRAINER ADRIAN R·Filed 2010·Application pending·0 cites
- 3731US2014298496A1Phenocopy model of diseaseKRAINER ADRIAN·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Adrian R. Krainer files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →